Medicare Part D Price Inflation Rebates Won’t Mean As Much In Inflationary Times
Executive Summary
Fewer rebate penalties than lawmakers expected may be assessed in the coming year because of the current high rate of general inflation.
You may also be interested in...
Eisai/Biogen’s Leqembi Will Launch Below Aduhelm At $26,500 Per Year
With accelerated approval granted and a supplemental filing for full approval in the FDA's hands, Eisai set a price it says is below the “societal value” its Alzheimer’s drug provides as it prepares to seek Medicare coverage. Labeling notably comes with no black box warning or safety restrictions despite various concerns.
Medicare ASP Reporting: CMS Weighing Guidance, Beefed Up Internal Controls To Ensure Accuracy
US Health and Human Services Department Inspector General issues two reports on manufacturer-reported average sales prices and how their accuracy could be improved. ASPs serve as the basis for Medicare Part B reimbursement and will also be used to guide implementation of price inflation-based rebate penalties for Part B drugs beginning in the first quarter of 2023.
Stock Watch: Will Static Pricing And Rising Inflation Compress Pharmaceutical Margins?
Generic pharmaceutical margins are notoriously thin while pricing is limited by intense competition. What happens to margins when raw material and energy pressures rise?